December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

0.2038 -0.0141 (-6.47%)
Streaming Delayed Price Updated: 9:57 AM EDT, May 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Barclays Downgrades Gossamer Bio: Here's What You Need To Know ↗
 
Via Benzinga
What 9 Analyst Ratings Have To Say About Gossamer Bio ↗
 
Via Benzinga
News headline image
ConocoPhillips To Rally Over 30%? Here Are 10 Other Price Target Changes For Wednesday ↗
Barclays raised ConocoPhillips (NYSE: COP) price target from $135 to $151. Barclays analyst Jeanine Wai maintained an Overweight rating on the stock. ConocoPhillips shares fell 3.2% to close at $115.61... 
Via Benzinga
News headline image
Dow Dips Over 500 Points; Nasdaq Down 2.5% ↗
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 2.5% on Tuesday. 
Via Benzinga
News headline image
Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis ↗
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Gossamer Bio ↗
 
Via Benzinga
Analyst Ratings for Gossamer Bio ↗
 
Via Benzinga
4 Analysts Have This to Say About Gossamer Bio ↗
 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Gossamer Bio ↗
Analysts have provided the following ratings for Gossamer Bio (NASDAQ:GOSS) within the last quarter: 
Via Benzinga
News headline image
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific... 
Via Benzinga
News headline image
Souring Sentiment On Wall Street Sends Dow Down Triple Digits ↗
Doubts over the Fed's next move are being compounded with renewed recession anxieties, and this sour sentiment is weighing on markets this afternoon. 
Via Talk Markets
News headline image
What 4 Analyst Ratings Have To Say About Gossamer Bio ↗
Within the last quarter, Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings: 
Via Benzinga
News headline image
Where Gossamer Bio Stands With Analysts ↗
Within the last quarter, Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings: 
Via Benzinga
News headline image
Analyst Ratings for Gossamer Bio ↗
Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
S&P 500 Down Over 1%; Crude Oil Falls Sharply ↗
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 250 points on Tuesday. 
Via Benzinga
News headline image
President Biden Is Bringing Taiwan Semi (TSM) Stock a HUGE Catalyst ↗
Taiwan Semiconductor (TSM) stock is on the move Tuesday as investors prepare for President Joe Biden to visit the company's Arizona plant. 
Via InvestorPlace
News headline image
Meta Platforms, Herbalife And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today? ↗
GOSS stock is plunging over 70%. The company's hypertension drug reportedly failed to perform better than a competing treatment. 
Via InvestorPlace
News headline image
Dow Drops 100 Points; US Trade Deficit Widens In October ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping around 100 points on Tuesday. 
Via Benzinga
News headline image
Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation ↗
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
From Gossamer Bio, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial ↗
 
Via Benzinga
News headline image
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022 ↗
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.